Otsuka & Lundbeck v. Mylan & Viatris: ABILIFY MAINTENA Generic Patent Battle Ends at 643 Days
Otsuka Pharmaceutical and H. Lundbeck sued Mylan NV, Mylan Pharmaceuticals, and Viatris in Delaware over eight patents protecting ABILIFY MAINTENA (aripiprazole extended-release injectable suspension). The case, covering 300 mg and 400 mg vial formulations, resolved by stipulation of dismissal after 643 days without a public merits ruling.
Eight-patent ABILIFY MAINTENA dispute ends by mutual stipulation in Delaware
On 26 August 2022, Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck AS filed a patent infringement action in the Delaware District Court (Case No. 1:22-cv-01125) against Mylan NV, Mylan Pharmaceuticals Inc., and Viatris Inc. The complaint asserted eight U.S. patents covering aripiprazole extended-release injectable suspension — marketed as ABILIFY MAINTENA in 300 mg and 400 mg vial formats — in response to the defendants’ ANDA filing seeking approval for generic versions of the product.
The case closed on 30 May 2024, approximately 643 days after filing, by way of a Stipulation of Dismissal. The available public record does not specify whether the dismissal was entered with or without prejudice. A stipulated dismissal of this nature typically signals that the parties reached a negotiated resolution — potentially a settlement or licensing arrangement — without the court issuing a merits ruling on validity, infringement, or enforceability of any of the eight asserted patents.
A duration of 643 days is consistent with ANDA patent cases that proceed through claim construction and early motion practice before settling. The eight-patent assertion covering both formulation and method claims suggests plaintiffs built a dense IP thicket around ABILIFY MAINTENA, which may have influenced the defendants’ calculus for negotiation. What drove the final resolution — including any entry date or licensing terms — remains confidential and is not disclosed in the public court record.
Filing to Case Dismissed in 643 days
643 days in litigation — above the median for Delaware Hatch-Waxman ANDA cases, suggesting substantive negotiation before resolution
Stipulated dismissal: what the outcome means for both parties
Stipulation of Dismissal: a negotiated exit, not a court verdict
A Stipulation of Dismissal means both parties agreed to end the litigation without a judicial ruling on the merits. No patent was held valid or invalid by the court, and no infringement finding was made. This mechanism is common in ANDA cases when the parties reach a private commercial resolution — typically a settlement agreement — that renders continued litigation unnecessary. The terms of any such agreement are not public.
No merits adjudicationPublic record is silent on prejudice status — an important distinction
Whether this dismissal was entered with or without prejudice carries significant practical consequences. Dismissal with prejudice would bar Otsuka and Lundbeck from re-filing the same claims against these defendants. Dismissal without prejudice would preserve that right. The available public record does not specify which applies here. Practitioners monitoring this dispute should treat the prejudice status as unconfirmed pending review of the actual stipulation filing.
Prejudice status unconfirmedMylan and Viatris: ANDA path remains uncertain without public settlement terms
For Mylan and Viatris, a stipulated dismissal without a public invalidity or non-infringement ruling means the patents asserted by Otsuka and Lundbeck remain formally intact. Any authorised generic entry date or patent licence granted to defendants as part of a settlement would be set by private agreement. The eight asserted patents — spanning formulation, method, and composition claims — continue to present enforcement risk against other potential ANDA filers.
Entry date terms undisclosedDense eight-patent thicket signals high barriers for aripiprazole injectable generics
Otsuka’s assertion of eight patents across multiple patent families covering ABILIFY MAINTENA is consistent with a layered exclusivity strategy common in long-acting injectable (LAI) antipsychotics. For other ANDA filers in this space, the survival of all eight patents without an invalidity ruling raises the cost and risk of challenging the IP thicket. R&D teams developing competing LAI formulations should assess freedom-to-operate against the full patent portfolio, not individual patents in isolation.
IP thicket strategy, LAI segmentFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Otsuka Pharmaceutical Co., Ltd. | Company | Pharmaceutical innovator and ABILIFY MAINTENA rights-holder — asserting US8030313B2 and 7 further aripiprazole injectable patentsSearch in Eureka ↗ |
| Co-Plaintiff | H. Lundbeck, AS | Individual | Search in Eureka ↗ |
| Defendant | Mylan, NV | Company | Generic pharmaceutical manufacturer (Mylan/Viatris) seeking ANDA approval for aripiprazole extended-release injectableSearch in Eureka ↗ |
| Co-Defendant | Mylan Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Viatris, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Andrew Mark Moshos | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Bindu Ann George Palapura | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Christine Dealy Haynes | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | David Ellis Moore | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Frederick L. Cottrell , III | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Jason James Rawnsley | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Potter, Anderson & Corroon LLP | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Richards, Layton & Finger, PA | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The recorded verdict of ‘Stipulation of Dismissal’ indicates both parties jointly moved to terminate the litigation before any dispositive or trial-level ruling. In Delaware Hatch-Waxman practice, this phrasing is procedurally neutral — it does not indicate which side prevailed commercially. The absence of a merits ruling means the court made no finding on the validity, enforceability, or infringement of any of the eight asserted patents, leaving all patents legally intact and enforceable against third parties.
US8030313B2 — Aripiprazole extended-release injectable suspension formulations
The eight patents asserted in this case cover multiple dimensions of ABILIFY MAINTENA’s technology: aripiprazole extended-release injectable suspension formulations, stabilisation methods, composition claims, and dosing methods. The portfolio spans application dates from the mid-2000s through to 2019, indicating a deliberate lifecycle management strategy. Aripiprazole is an atypical antipsychotic; the injectable extended-release format addresses adherence limitations of oral dosing, making the formulation patents commercially critical.
The breadth of the eight-patent portfolio — covering formulation, method, and composition claims across multiple patent families — is consistent with an aggressive exclusivity strategy for a high-value long-acting injectable antipsychotic. ABILIFY MAINTENA is a multi-hundred-million-dollar product globally. For competitors developing LAI antipsychotic generics or next-generation formulations, the survival of all eight patents without judicial invalidation represents a substantial IP barrier that will require either licensing, IPR challenges, or design-around strategies before commercial launch.
Should you run an FTO analysis against the ABILIFY MAINTENA patent portfolio?
Any company developing or commercialising generic or novel extended-release injectable aripiprazole formulations — whether for ANDA, 505(b)(2), or new drug applications — should conduct a comprehensive freedom-to-operate analysis against all eight patents asserted in this case. The portfolio’s multi-layered coverage of formulation, method, and composition claims means that designing around a single patent is insufficient. R&D teams should map their process and product against each patent family independently.
PatSnap Eureka’s FTO Search Agent can map each of the eight asserted patents — from US8030313B2 to US11154553B1 — against your formulation specifications and manufacturing methods, flagging claim-by-claim overlap and identifying design-around opportunities. Eureka can also surface expired or expiring claims within the portfolio and monitor FDA Orange Book listings to track when exclusivity windows are projected to open for aripiprazole extended-release injectables.
Run a freedom-to-operate analysis on US8030313B2 to assess your product’s exposure
Run FTO in Eureka →Similar aripiprazole injectable and Hatch-Waxman ANDA patent cases
Explore related patent infringement actions involving long-acting injectable antipsychotic formulations and ANDA challenges filed in Delaware District Court.
What this case signals for the aripiprazole injectable IP landscape
Eight asserted patents, 643 days, no public merits ruling — the strategic implications for ABILIFY MAINTENA’s exclusivity extend well beyond this docket.
All eight patents survive without an invalidity ruling — enforcement risk remains high
Because the case resolved by stipulated dismissal without a merits decision, none of the eight asserted patents were adjudicated invalid or unenforceable. For any company developing generic or biosimilar aripiprazole extended-release injectables, these patents remain fully enforceable. Each new ANDA filing will need to address the full eight-patent portfolio, maintaining a high barrier to generic entry.
Stipulated dismissals after 600+ days suggest mature negotiation — not early weakness
A resolution after 643 days is consistent with litigation that progressed through substantive stages before the parties reached commercial terms. This timeline suggests the defendants did not secure an early dismissal on procedural grounds. Observers should not interpret the outcome as a concession by either side — it more likely reflects a negotiated entry date or licensing arrangement aligned with expiry of certain patent claims.
Otsuka v Mylan — key questions answered
Otsuka and Lundbeck asserted eight U.S. patents: US8030313B2, US10525057B2, US8722679B2, US8338427B2, US8399469B2, US10980803B2, US7807680B2, and US11154553B1. All cover aspects of aripiprazole extended-release injectable suspension — the formulation marketed as ABILIFY MAINTENA — including composition, method, and dosing claims across multiple patent families.
The case was terminated by a Stipulation of Dismissal, meaning both parties agreed to end the litigation without a court ruling on patent validity or infringement. This mechanism is common in Hatch-Waxman ANDA cases when a commercial resolution — such as a settlement or licence — has been reached privately. It does not indicate which party prevailed; any licensing or entry date terms remain confidential.
The available public record does not specify whether the Stipulation of Dismissal was entered with or without prejudice. This distinction matters significantly: dismissal with prejudice bars re-filing of the same claims; without prejudice preserves that right. Practitioners should review the actual stipulation filing on PACER to confirm the prejudice status before drawing enforcement or re-filing conclusions.
ABILIFY MAINTENA is an atypical antipsychotic (aripiprazole) formulated as an extended-release injectable suspension in 300 mg and 400 mg vials, designed for monthly dosing to improve adherence over oral formulations. The eight-patent portfolio reflects a lifecycle management strategy — layering formulation, method, composition, and dosing patents filed across multiple application dates to extend exclusivity and deter generic competition.
Because the case resolved without a merits ruling, all eight asserted patents remain valid and enforceable on the public record. Companies developing generic or novel extended-release aripiprazole injectable products must conduct freedom-to-operate analyses against the full portfolio. No judicial finding of invalidity or non-infringement was made, and the absence of a public settlement timeline means the competitive window for generic entry remains uncertain without independent legal analysis.
PatSnap Eureka searches patents and litigation data to answer instantly.